These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22892550)

  • 21. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid and complete donor chimerism after unrelated mismatched cord blood transplantation in 5 children with beta-thalassemia major.
    Jaing TH; Hung IJ; Yang CP; Chen SH; Sun CF; Chow R
    Biol Blood Marrow Transplant; 2005 May; 11(5):349-53. PubMed ID: 15846288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
    Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
    Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haematopoietic stem cell transplantation for thalassaemia major in Hong Kong: prognostic factors and outcome.
    Li CK; Shing MM; Chik KW; Lee V; Leung TF; Cheung AY; Yuen MP
    Bone Marrow Transplant; 2002 Jan; 29(2):101-5. PubMed ID: 11850702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
    McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
    Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
    Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA-matched family hematopoetic stem cell transplantation in children with beta thalassemia major: the experience of the Turkish Pediatric Bone Marrow Transplantation Group.
    Yesilipek MA; Ertem M; Cetin M; Öniz H; Kansoy S; Tanyeli A; Anak S; Kurekci E; Hazar V
    Pediatr Transplant; 2012 Dec; 16(8):846-51. PubMed ID: 22931438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
    Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
    Resnick IB; Aker M; Tsirigotis P; Shapira MY; Abdul-Hai A; Bitan M; Gesundheit B; Amar A; Ackerstein A; Samuel S; Slavin S; Or R
    Bone Marrow Transplant; 2007 Nov; 40(10):957-64. PubMed ID: 17846604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
    Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
    Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pretreatment doses of antithymocyte globubin-fresenius for allogeneic hematopoietic stem cell transplantation for beta-thalassemia major].
    Li C; Wang Y; Wu X; Pei F; He Y; Feng X; Liu H
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 May; 32(5):691-4. PubMed ID: 22588927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
    Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G
    Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation.
    Caocci G; Efficace F; Ciotti F; Roncarolo MG; Vacca A; Piras E; Littera R; Dawood Markous RS; Collins GS; Ciceri F; Mandelli F; Marktel S; La Nasa G
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):861-6. PubMed ID: 20870029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.
    Anurathapan U; Pakakasama S; Mekjaruskul P; Sirachainan N; Songdej D; Chuansumrit A; Charoenkwan P; Jetsrisuparb A; Sanpakit K; Pongtanakul B; Rujkijyanont P; Meekaewkunchorn A; Sruamsiri R; Ungkanont A; Issaragrisil S; Andersson BS; Hongeng S
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2066-71. PubMed ID: 25064743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India.
    Swaminathan VV; Uppuluri R; Patel S; Ravichandran N; Ramanan KM; Vaidhyanathan L; Ramakrishnan B; Jayakumar I; Raj R
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.